Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'

An urgent requirement exists for new prognostic and predictive assays in breast cancer. Despite the development of high-throughput technologies such as DNA microarrays, it would now appear that immunohistochemistry (IHC) may play an increasingly important role in the clinical management of breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Donal J, Gallagher, William M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374964/
https://www.ncbi.nlm.nih.gov/pubmed/18331621
http://dx.doi.org/10.1186/bcr1854
_version_ 1782154547394772992
author Brennan, Donal J
Gallagher, William M
author_facet Brennan, Donal J
Gallagher, William M
author_sort Brennan, Donal J
collection PubMed
description An urgent requirement exists for new prognostic and predictive assays in breast cancer. Despite the development of high-throughput technologies such as DNA microarrays, it would now appear that immunohistochemistry (IHC) may play an increasingly important role in the clinical management of breast cancer. In this editorial, the authors discuss the potential prognostic ability of a panel of IHC markers, and question whether this well-established assay technology may in fact allow for improved prognostic and predictive tests in breast cancer.
format Text
id pubmed-2374964
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23749642008-05-10 Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution' Brennan, Donal J Gallagher, William M Breast Cancer Res Editorial An urgent requirement exists for new prognostic and predictive assays in breast cancer. Despite the development of high-throughput technologies such as DNA microarrays, it would now appear that immunohistochemistry (IHC) may play an increasingly important role in the clinical management of breast cancer. In this editorial, the authors discuss the potential prognostic ability of a panel of IHC markers, and question whether this well-established assay technology may in fact allow for improved prognostic and predictive tests in breast cancer. BioMed Central 2008 2008-02-25 /pmc/articles/PMC2374964/ /pubmed/18331621 http://dx.doi.org/10.1186/bcr1854 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Editorial
Brennan, Donal J
Gallagher, William M
Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title_full Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title_fullStr Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title_full_unstemmed Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title_short Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
title_sort prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374964/
https://www.ncbi.nlm.nih.gov/pubmed/18331621
http://dx.doi.org/10.1186/bcr1854
work_keys_str_mv AT brennandonalj prognosticabilityofapanelofimmunohistochemistrymarkersretailoringofanoldsolution
AT gallagherwilliamm prognosticabilityofapanelofimmunohistochemistrymarkersretailoringofanoldsolution

Ejemplares similares